Cadila Healthcare

Cadila Healthcare Ltd (Zydus Cadila) also known as Zydus Healthcare is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is one of the leading pharmaceutical companies in India,[3] with a total revenue of ₹7,104.30 crore (US$1.0 billion) in 2019.[4] It is a manufacturer of generic drugs.[5]

Zydus Cadila Healthcare Limited
Public (BSE: 532321)
Traded asBSE:532321
IndustryPharmaceuticals
Founded1952
FounderRamanbhai Patel
HeadquartersAhmedabad, Gujarat, India
Key people
Pankaj R. Patel, Chairman, Sharvil P. Patel, Managing Director
Revenue7,104.30 crore (US$1.0 billion) [1] (2019)
1,602.10 crore (US$220 million) [2] (2019)
Number of employees
13180 (2015)
Websitewww.zyduscadila.com

History

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321.

In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.[6]

In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.

In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price.[7] Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015.[5]

In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.

Products

From nine pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep).[8]

The company makes active pharmaceutical ingredients at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.

Corporate control

Zydus Cadila's major shareholder remains the Patel family. Pankaj Patel (born 1951), son of the founder, is Chairman of the company. In 2004 Pankaj Patel was included by Forbes magazine in its annual List of India's richest people. As of 2020 Forbes estimates Patel's net worth at US $3.9 billion, making him India's 46th richest person.[9]

References

  1. "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  2. "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  3. "A Complete Overview on Cadila Healthcare, a growing and popular company in India". business.mapsofindia.com. 21 June 2011. Retrieved 4 February 2009.
  4. "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  5. "Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences". The Hindu Business Line. 17 March 2015. Retrieved 29 December 2017.
  6. Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda Bloomberg
  7. Zydus Cadila launches biosimilar of AbbVie's Humira in India The Economic Times 9 December 2014
  8. "Hepatitis C treatment in India for less than $1000". hep-c-news.com. Hep C News. 11 July 2016. Archived from the original on 16 September 2016.
  9. "Pankaj Patel". Forbes. Retrieved 15 June 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.